<DOC>
	<DOCNO>NCT00794274</DOCNO>
	<brief_summary>To determine whether CC-10004 , phosphodiesterase inhibitor , useful treat chronic cutaneous sarcoidosis .</brief_summary>
	<brief_title>The Efficacy Safety CC-10004 Chronic Cutaneous Sarcoidosis</brief_title>
	<detailed_description>This open label , phase II trial CC-10004 chronic cutaneous sarcoidosis . It include two center ( University Cincinnati Medical University South Carolina ) . The study evaluate patient chronic disease stable treatment regimen significant change Sarcoidosis Skin Activity Severity Index score ( SASI ) two visit least one month apart .</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form Must male female age ≥ 18 year time consent Must able adhere study visit schedule protocol requirement Patients sarcoidosis define ATS/ERS/WASOG statement sarcoidosis define clinical presentation consistent sarcoidosis , biopsy find granuloma , alternative cause granuloma , tuberculosis Patients must chronic cutaneous skin lesion take chronic therapy ( corticosteroid , methotrexate ( max 10mg/week ) , azathioprine , hydroxychloroquine , cyclophosphamide , minocycline , doxycycline chloroquine ) , dose alter three month prior start study . Must two visit within previous 16 month ( least one month apart ) stable skin lesion , SASI score within one point feature lesion . Must meet follow laboratory criterion : Hemoglobin &gt; 9 g/dL Hematocrit ≥ 27 % White blood cell ( WBC ) count ≥ 3000 ( ≥ 3.0 X 109/L ) &lt; 20,000 ( &lt; 20 X 109/L ) Neutrophils ≥ 1500 ( ≥ 1.5 X 109/L ) Platelets ≥ 100,000 ( ≥ 100 X 109/L ) Serum creatinine ≤ 1.5 mg/dL ( ≤ 132.6 μmol/L ) Total bilirubin &lt; 2.0 mg/dL Aspartate transaminase ( AST [ serum glutamic oxaloacetic transaminase , SGOT ] ) alanine transaminase ( ALT [ serum glutamate pyruvic transaminase , SGPT ] ) &lt; 1.5x upper limit normal ( ULN ) Females childbearing potential ( FCBP ) ‡ must negative urine pregnancy test screening ( Visit 1 ) . In addition , sexually active FCBP must agree use TWO follow adequate form contraception study medication : oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive vasectomized partner . A FCBP must agree pregnancy test every 28 day study medication . Males ( include vasectomy ) must agree use barrier contraception ( latex condom ) engage sexual activity FCBP study medication 84 day take last dose study medication . History clinically significant cardiac , endocrinologic , pulmonary , neurologic , psychiatric , hepatic , renal , hematologic , immunologic , major disease ( include pulmonary sarcoidosis ) Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Pregnant lactate female History active Mycobacterium tuberculosis infection ( subspecies ) within 3 year prior screen visit . Infections occur &gt; 3 year prior entry must effectively treat . History incompletely treat latent Mycobacterium tuberculosis infection ( indicated positive Purified Protein Derivative [ PPD ] skin test vitro test [ TSPOT®.TB , QuantiFERON Gold® ] . Clinically significant abnormality chest xray ( CXR ) screen due sarcoidosis Use investigational medication within 28 day . Any clinically significant abnormality 12lead ECG screen Positive human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C laboratory test result indicate active infection screen History malignancy within previous 5 year ( except treat basalcell skin carcinoma ( ) and/or few 3 treat squamouscell skin carcinoma ) Use infliximab , etanercept , adalimumab , pentoxifylline , thalidomide prior three month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Sarcodiosis</keyword>
	<keyword>tumor necrosis factor</keyword>
</DOC>